T1	Participants 49 115	predominantly classic neovascular age-related macular degeneration
T2	Participants 308 401	Predominantly Classic Choroidal Neovascularization [CNV] in Age-Related Macular Degeneration)
T3	Participants 490 591	423 patients received ranibizumab (0.3 or 0.5 mg) monthly + sham PDT or PDT + monthly sham injection.
